449 related articles for article (PubMed ID: 25263564)
1. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract][Full Text] [Related]
2. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Di Mitri D; Toso A; Chen JJ; Sarti M; Pinton S; Jost TR; D'Antuono R; Montani E; Garcia-Escudero R; Guccini I; Da Silva-Alvarez S; Collado M; Eisenberger M; Zhang Z; Catapano C; Grassi F; Alimonti A
Nature; 2014 Nov; 515(7525):134-7. PubMed ID: 25156255
[TBL] [Abstract][Full Text] [Related]
3. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Hancox U; Cosulich S; Hanson L; Trigwell C; Lenaghan C; Ellston R; Dry H; Crafter C; Barlaam B; Fitzek M; Smith PD; Ogilvie D; D'Cruz C; Castriotta L; Wedge SR; Ward L; Powell S; Lawson M; Davies BR; Harrington EA; Foster E; Cumberbatch M; Green S; Barry ST
Mol Cancer Ther; 2015 Jan; 14(1):48-58. PubMed ID: 25398829
[TBL] [Abstract][Full Text] [Related]
5. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Kalathur M; Toso A; Chen J; Revandkar A; Danzer-Baltzer C; Guccini I; Alajati A; Sarti M; Pinton S; Brambilla L; Di Mitri D; Carbone G; Garcia-Escudero R; Padova A; Magnoni L; Tarditi A; Maccari L; Malusa F; Kalathur RK; A Pinna L; Cozza G; Ruzzene M; Delaleu N; Catapano CV; Frew IJ; Alimonti A
Nat Commun; 2015 Jun; 6():7227. PubMed ID: 26085373
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
[TBL] [Abstract][Full Text] [Related]
7. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
[TBL] [Abstract][Full Text] [Related]
8. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging.
Muñoz DP; Yannone SM; Daemen A; Sun Y; Vakar-Lopez F; Kawahara M; Freund AM; Rodier F; Wu JD; Desprez PY; Raulet DH; Nelson PS; van 't Veer LJ; Campisi J; Coppé JP
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31184599
[TBL] [Abstract][Full Text] [Related]
9. NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence.
Manda KR; Tripathi P; Hsi AC; Ning J; Ruzinova MB; Liapis H; Bailey M; Zhang H; Maher CA; Humphrey PA; Andriole GL; Ding L; You Z; Chen F
Oncogene; 2016 Jun; 35(25):3282-92. PubMed ID: 26477312
[TBL] [Abstract][Full Text] [Related]
10. A miR-335/COX-2/PTEN axis regulates the secretory phenotype of senescent cancer-associated fibroblasts.
Kabir TD; Leigh RJ; Tasena H; Mellone M; Coletta RD; Parkinson EK; Prime SS; Thomas GJ; Paterson IC; Zhou D; McCall J; Speight PM; Lambert DW
Aging (Albany NY); 2016 Aug; 8(8):1608-35. PubMed ID: 27385366
[TBL] [Abstract][Full Text] [Related]
11. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
12. Methylseleninic Acid Superactivates p53-Senescence Cancer Progression Barrier in Prostate Lesions of Pten-Knockout Mouse.
Wang L; Guo X; Wang J; Jiang C; Bosland MC; Lü J; Deng Y
Cancer Prev Res (Phila); 2016 Jan; 9(1):35-42. PubMed ID: 26511486
[TBL] [Abstract][Full Text] [Related]
13. Distinct phenotypes and 'bystander' effects of senescent tumour cells induced by docetaxel or immunomodulatory cytokines.
Sapega O; Mikyšková R; Bieblová J; Mrázková B; Hodný Z; Reiniš M
Int J Oncol; 2018 Nov; 53(5):1997-2009. PubMed ID: 30226595
[TBL] [Abstract][Full Text] [Related]
14. [How to limit the progression of PTEN-deficient prostatic tumors?].
Grelet É; Parisotto M; Metzger D
Med Sci (Paris); 2018 Nov; 34(11):904-906. PubMed ID: 30526823
[No Abstract] [Full Text] [Related]
15. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.
Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16392-7. PubMed ID: 21930937
[TBL] [Abstract][Full Text] [Related]
16. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade Prostate Cancer Senescence.
Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
[TBL] [Abstract][Full Text] [Related]
17. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
18. Autophagy and PTEN in DNA damage-induced senescence.
Sharma A; Almasan A
Adv Cancer Res; 2021; 150():249-284. PubMed ID: 33858598
[TBL] [Abstract][Full Text] [Related]
19. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
[TBL] [Abstract][Full Text] [Related]
20. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells.
Schwarze SR; Fu VX; Desotelle JA; Kenowski ML; Jarrard DF
Neoplasia; 2005 Sep; 7(9):816-23. PubMed ID: 16229804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
